Argenx
ARGX
#408
Rank
$57.04 B
Marketcap
$915.97
Share price
-0.63%
Change (1 day)
46.56%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

P/E ratio for Argenx (ARGX)

P/E ratio as of December 2025 (TTM): 103

According to Argenx 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 103.266. At the end of 2024 the company had a P/E ratio of 44.5.

P/E ratio history for Argenx from 2018 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202444.5-160.41%
2023-73.7153.98%
2022-29.0-34.3%
2021-44.298.94%
2020-22.2-35.11%
2019-34.2-26.63%
2018-46.61.05%
2017-46.2

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.